{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:46:16Z","timestamp":1771328776819,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05057-3","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:01:51Z","timestamp":1716375711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-8569","authenticated-orcid":false,"given":"Simone","family":"Morra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reha-Baris","family":"Incesu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Scheipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Baudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia Maria Ippolita","family":"Jannello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Creta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Califano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Coll\u00e0 Ruvolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Ahyai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"5057_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","volume":"73","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Dalbagni G, Daneshmand S et al (2018) The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol 73:543\u2013557. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.030","journal-title":"Eur Urol"},{"key":"5057_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.euf.2017.11.012","volume":"5","author":"M Marchioni","year":"2019","unstructured":"Marchioni M, Bandini M, Preisser F et al (2019) Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: a population-based study. Eur Urol Focus 5:488\u2013496. https:\/\/doi.org\/10.1016\/j.euf.2017.11.012","journal-title":"Eur Urol Focus"},{"key":"5057_CR3","doi-asserted-by":"publisher","first-page":"e730","DOI":"10.1016\/j.clgc.2020.05.009","volume":"18","author":"C Palumbo","year":"2020","unstructured":"Palumbo C, Mistretta FA, Knipper S et al (2020) Contemporary cytoreductive nephrectomy provides survival benefit in clear-cell metastatic renal cell carcinoma. Clin Genitourin Cancer 18:e730\u2013e738. https:\/\/doi.org\/10.1016\/j.clgc.2020.05.009","journal-title":"Clin Genitourin Cancer"},{"key":"5057_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.euf.2020.04.009","volume":"7","author":"S Luzzago","year":"2021","unstructured":"Luzzago S, Palumbo C, Rosiello G et al (2021) Association between systemic therapy and\/or cytoreductive nephrectomy and survival in contemporary metastatic non\u2013clear cell renal cell carcinoma patients. Eur Urol Focus 7:598\u2013607. https:\/\/doi.org\/10.1016\/j.euf.2020.04.009","journal-title":"Eur Urol Focus"},{"key":"5057_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.clgc.2022.08.010","volume":"21","author":"A Panunzio","year":"2023","unstructured":"Panunzio A, Sorce G, Tappero S et al (2023) Mortality according to treatment in metastatic collecting duct renal cell carcinoma. Clin Genitourin Cancer 21:295\u2013300. https:\/\/doi.org\/10.1016\/j.clgc.2022.08.010","journal-title":"Clin Genitourin Cancer"},{"key":"5057_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.02.010","author":"S Tappero","year":"2023","unstructured":"Tappero S, Barletta F, Piccinelli ML et al (2023) The association between cytoreductive nephrectomy and overall survival in metastatic renal cell carcinoma with primary tumor size \u22644 cm. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2023.02.010","journal-title":"Eur Urol Focus"},{"key":"5057_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10585-018-9884-z","volume":"34","author":"F Dong","year":"2017","unstructured":"Dong F, Fu H, Shi X et al (2017) How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. Clin Exp Metastasis 34:467\u2013477. https:\/\/doi.org\/10.1007\/s10585-018-9884-z","journal-title":"Clin Exp Metastasis"},{"key":"5057_CR8","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/j.clgc.2019.03.003","volume":"17","author":"S Nazzani","year":"2019","unstructured":"Nazzani S, Preisser F, Mazzone E et al (2019) Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 17:e602\u2013e611. https:\/\/doi.org\/10.1016\/j.clgc.2019.03.003","journal-title":"Clin Genitourin Cancer"},{"key":"5057_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","volume":"71","author":"T Seisen","year":"2017","unstructured":"Seisen T, Jindal T, Karabon P et al (2017) Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma. Eur Urol 71:714\u2013718. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.012","journal-title":"Eur Urol"},{"key":"5057_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","volume":"3","author":"M Moschini","year":"2020","unstructured":"Moschini M, Xylinas E, Zamboni S et al (2020) Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database. Eur Urol Oncol 3:94\u2013101. https:\/\/doi.org\/10.1016\/j.euo.2019.06.014","journal-title":"Eur Urol Oncol"},{"key":"5057_CR11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jso.25840","volume":"121","author":"G Rosiello","year":"2020","unstructured":"Rosiello G, Palumbo C, Deuker M et al (2020) Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. J Surg Oncol 121:688\u2013696. https:\/\/doi.org\/10.1002\/jso.25840","journal-title":"J Surg Oncol"},{"key":"5057_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11934-016-0595-1","volume":"17","author":"JD Raman","year":"2016","unstructured":"Raman JD, Jafri SM (2016) Complications following radical nephroureterectomy. Curr Urol Rep 17:36. https:\/\/doi.org\/10.1007\/s11934-016-0595-1","journal-title":"Curr Urol Rep"},{"key":"5057_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ et al (2020) Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol 203:690\u2013698. https:\/\/doi.org\/10.1097\/JU.0000000000000644","journal-title":"J Urol"},{"key":"5057_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.eururo.2020.04.008","volume":"78","author":"G Califano","year":"2020","unstructured":"Califano G, Xylinas E (2020) Re: phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. Eur Urol 78:113\u2013114. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.008","journal-title":"Eur Urol"},{"key":"5057_CR15","unstructured":"SEER cancer statistics review, 1975\u20132018. In: SEER. https:\/\/seer.cancer.gov\/csr\/1975_2018\/index.html. Accessed 14 Jan 2023"},{"key":"5057_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM et al (2022) The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2014part B: prostate and urinary tract tumors. Eur Urol 82:469\u2013482. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.002","journal-title":"Eur Urol"},{"key":"5057_CR17","unstructured":"R: the R project for statistical computing. https:\/\/www.r-project.org\/. Accessed 14 Jan 2023"},{"key":"5057_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"5057_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M et al (2021) European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79:62\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.042","journal-title":"Eur Urol"},{"key":"5057_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.01.034","author":"S Morra","year":"2024","unstructured":"Morra S, Scheipner L, Baudo A et al (2024) Regional differences in upper tract urothelial carcinoma patients across the United States. Urol Oncol Semin Orig Investig. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.034","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"5057_CR21","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00345-022-04156-3","volume":"40","author":"A Tafuri","year":"2022","unstructured":"Tafuri A, Marchioni M, Cerrato C et al (2022) Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). World J Urol 40:2771\u20132779. https:\/\/doi.org\/10.1007\/s00345-022-04156-3","journal-title":"World J Urol"},{"key":"5057_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00345-023-04344-9","volume":"41","author":"C Cerrato","year":"2023","unstructured":"Cerrato C, Pandolfo SD, Autorino R et al (2023) Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome. World J Urol 41:1741\u20131749. https:\/\/doi.org\/10.1007\/s00345-023-04344-9","journal-title":"World J Urol"},{"key":"5057_CR23","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/cncr.24147","volume":"115","author":"KA David","year":"2009","unstructured":"David KA, Mallin K, Milowsky MI et al (2009) Surveillance of urothelial carcinoma: Stage and grade migration, 1993\u20132005 and survival trends, 1993\u20132000. Cancer 115:1435\u20131447. https:\/\/doi.org\/10.1002\/cncr.24147","journal-title":"Cancer"},{"key":"5057_CR24","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/j.clgc.2018.01.015","volume":"16","author":"BM Browne","year":"2018","unstructured":"Browne BM, Stensland KD, Moynihan MJ, Canes D (2018) An analysis of staging and treatment trends for upper tract urothelial carcinoma in the National Cancer Database. Clin Genitourin Cancer 16:e743\u2013e750. https:\/\/doi.org\/10.1016\/j.clgc.2018.01.015","journal-title":"Clin Genitourin Cancer"},{"key":"5057_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","volume":"4","author":"C Coll\u00e0 Ruvolo","year":"2021","unstructured":"Coll\u00e0 Ruvolo C, Nocera L, Stolzenbach LF et al (2021) Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma. Eur Urol Oncol 4:792\u2013801. https:\/\/doi.org\/10.1016\/j.euo.2020.11.005","journal-title":"Eur Urol Oncol"},{"key":"5057_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00345-016-1848-9","volume":"35","author":"MD Vartolomei","year":"2017","unstructured":"Vartolomei MD, Mathieu R, Margulis V et al (2017) Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol 35:121\u2013130. https:\/\/doi.org\/10.1007\/s00345-016-1848-9","journal-title":"World J Urol"},{"key":"5057_CR27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00345-023-04449-1","volume":"41","author":"M von Deimling","year":"2023","unstructured":"von Deimling M, D\u2019Andrea D, Pradere B et al (2023) Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma. World J Urol 41:1861\u20131868. https:\/\/doi.org\/10.1007\/s00345-023-04449-1","journal-title":"World J Urol"},{"key":"5057_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00345-023-04379-y","volume":"41","author":"V Egger","year":"2023","unstructured":"Egger V, Hutterer GC, Mischinger J et al (2023) Preoperative fibrinogen\/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery. World J Urol 41:1359\u20131364. https:\/\/doi.org\/10.1007\/s00345-023-04379-y","journal-title":"World J Urol"},{"key":"5057_CR29","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.clgc.2018.09.017","volume":"17","author":"S Nazzani","year":"2019","unstructured":"Nazzani S, Preisser F, Mazzone E et al (2019) Survival effect of chemotherapy in metastatic upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 17:e97\u2013e103. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.017","journal-title":"Clin Genitourin Cancer"},{"key":"5057_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00345-020-03502-7","volume":"39","author":"G Califano","year":"2021","unstructured":"Califano G, Ouzaid I, Verze P et al (2021) Immune checkpoint inhibition in upper tract urothelial carcinoma. World J Urol 39:1357\u20131367. https:\/\/doi.org\/10.1007\/s00345-020-03502-7","journal-title":"World J Urol"},{"key":"5057_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/curroncol29020060","volume":"29","author":"G Califano","year":"2022","unstructured":"Califano G, Ouzaid I, Laine-Caroff P et al (2022) Current advances in immune checkpoint inhibition and clinical genomics in upper tract urothelial carcinoma: state of the art. Curr Oncol Tor Ont 29:687\u2013697. https:\/\/doi.org\/10.3390\/curroncol29020060","journal-title":"Curr Oncol Tor Ont"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05057-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:31:45Z","timestamp":1735853505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5057"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05057-3","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shahrokh F. Shariat: Horonraria: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Consulting or Advisory Role: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Speakers\u2019 Bureau: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen, Movember Foundation. Patents: Method to determine prognosis after therapy for prostate cancer\u2014granted 2002-09-06, Methods to determine prognosis after therapy for bladder cancer\u2014granted 2003-06-19, Prognostic methods for patients with prostatic disease\u2014granted 2004-08-05; Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma\u2014granted 2010-07-20. Our research was conducted without any other potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study\u2010 specific Institutional Review Board ethics approval as not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics consent statement"}}],"article-number":"343"}}